Eledon Pharmaceuticals, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Eledon Pharmaceuticals, Inc. (ELDN), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are ELDN insiders buying or selling?
Eledon Pharmaceuticals, Inc. insiders reported no open-market purchases or sales in the last 12 months. Since September 2018, Trabud has recorded 17 Form 4 filings for ELDN: 12 buys ($6.3M) and 5 sells ($2.3M).
Source: SEC EDGAR Form 4
Key Statistics (September 2018 – May 13, 2024)
Total Form 4 filings
17
SEC EDGAR
Insider filers
11
Insider buys (12)
$6.3M
Insider sells (5)
$2.3M
Insider sentiment
Net buyingNet insider flow of $4.0M in net buying since September 2018.
Recent ELDN insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| May 13, 2024 | Mark N Lampert | 10% Owner | Purchase | 1.9M | $0.00 | $0 | SEC ↗ |
| May 10, 2023 | Mark N Lampert | 10% Owner | Purchase | 2.0M | $0.00 | $0 | SEC ↗ |
| Nov 23, 2022 | Steven Perrin | President | Purchase | 1.0K | $2.60 | $2.6K | SEC ↗ |
| Dec 21, 2021 | David-Alexandre C Gros | Chief Executive Officer | Purchase | 2.0K | $4.48 | $9.0K | SEC ↗ |
| Aug 19, 2021 | David-Alexandre C Gros | Chief Executive Officer | Purchase | 4.0K | $6.21 | $24.8K | SEC ↗ |
| Jun 14, 2021 | Paul Sean Little | CHIEF FINANCIAL OFFICER | Purchase | 10.0K | $8.87 | $88.7K | SEC ↗ |
| Jun 10, 2021 | David-Alexandre C Gros | Chief Executive Officer | Purchase | 3.0K | $8.01 | $24.0K | SEC ↗ |
| Dec 4, 2020 | OrbiMed Israel GP Ltd. | 10% Owner | Sale | 103.2K | $21.60 | $2.2M | SEC ↗ |
| Nov 6, 2020 | Logos Global Management LP | 10% Owner | Purchase | 79.1K | $25.25 | $2.0M | SEC ↗ |
| May 22, 2019 | Catherine C. Turkel | President | Sale | 9.5K | $1.95 | $18.6K | SEC ↗ |
| May 22, 2019 | Jon Kuwahara | Officer | Sale | 5.3K | $1.95 | $10.3K | SEC ↗ |
| May 22, 2019 | Gregory J. Flesher | Chief Executive Officer | Sale | 14.6K | $1.95 | $28.6K | SEC ↗ |
| May 6, 2019 | OrbiMed Israel GP Ltd. | Director, 10% Owner | Purchase | 646.2K | $3.10 | $2.0M | SEC ↗ |
| May 6, 2019 | Erez Chimovits | Director | Purchase | 646.2K | $3.10 | $2.0M | SEC ↗ |
| May 2, 2019 | LIFESCI INDEX PARTNERS LLC | 10% Owner | Sale | 200 | $2.70 | $540 | SEC ↗ |
| Sep 14, 2018 | Catherine C. Turkel | President | Purchase | 33.7K | $4.78 | $161.1K | SEC ↗ |
| Sep 8, 2018 | Catherine C. Turkel | President | Purchase | 805 | $3.97 | $3.2K | SEC ↗ |
Showing the 17 most recent of 17 Form 4 filings for Eledon Pharmaceuticals, Inc..
Most active ELDN insiders
- Catherine C. Turkel3 filings
- David-Alexandre C Gros3 filings
- OrbiMed Israel GP Ltd.2 filings
- Mark N Lampert2 filings
- Erez Chimovits1 filing
Ask anything about ELDN insider activity
Use Trabud's AI agent to query Eledon Pharmaceuticals, Inc.'s Form 4 history in plain English — "Show me ELDN CEO purchases this year" or compare it against any other ticker.
Open the AI agentELDN insider trading FAQ
Are Eledon Pharmaceuticals, Inc. insiders buying or selling?
Eledon Pharmaceuticals, Inc. insiders reported no open-market purchases or sales in the last 12 months. Since September 2018, Trabud has recorded 17 Form 4 filings for ELDN: 12 buys ($6.3M) and 5 sells ($2.3M). Over the full record that is net buying of $4.0M.
How many insiders trade ELDN stock?
11 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Eledon Pharmaceuticals, Inc.. The most recent filing was accepted on May 13, 2024.
Where does Trabud get ELDN insider trading data?
All ELDN insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.